Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity.

Min CK, Cheon S, Ha NY, Sohn KM, Kim Y, Aigerim A, Shin HM, Choi JY, Inn KS, Kim JH, Moon JY, Choi MS, Cho NH, Kim YS. · 2016

Read Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. by Min CK, Cheon S, Ha NY, Sohn KM, Kim Y, Aigerim A, Shin HM, Choi JY, Inn KS, Kim JH, Moon JY, Choi MS, Cho NH, Kim YS. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4857172.txt.

Introduction

Chan-Ki Min and co-authors compared virus shedding and immune responses in 14 MERS patients in 2016, spanning mild fever to fatal pneumonia. MERS, a severe lung infection, still lacks clear rules for what drives a bad outcome. Patients were grouped by severity and survival, and blood and virus measures were tracked over time.

Death tracked with high virus loads, weak antibody responses, and low lymphocyte counts paired with low platelets. Severe cases showed more white cells of other types, chiefly neutrophils and monocytes. Steady, rising lymphocyte responses seemed needed to beat the virus. Several blood signal proteins rose or fell with survival, giving doctors candidate warning signs.

Catalog record

CREATORMin CK, Cheon S, Ha NY, Sohn KM, Kim Y, Aigerim A, Shin HM, Choi JY, Inn KS, Kim JH, Moon JY, Choi MS, Cho NH, Kim YS.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4857172

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity By Chan-Ki Min, Shinhye Cheon, Na-Young Ha, Kyung Mok Sohn, Yuri Kim, Abdimadiyeva Aigerim, Hyun Mu Shin, Ji-Yeob Choi, Kyung-Soo Inn, Jin-Hwan Kim, Jae Young Moon, Myung-Sik Choi Published in: Scientific Reports DOI: 10.1038/srep25359 ABSTRACT Despite the ongoing spread of MERS, there is limited knowledge of the factors affecting its severity and outcomes. We analyzed clinical data and specimens from fourteen MERS patients treated in a hospital who collectively represent a wide spectrum of disease severity, ranging from mild febrile illness to fatal pneumonia, and classified the patients into four groups based on severity and mortality. Comparative and kinetic analyses revealed that high viral loads, weak antibody responses, and lymphopenia accompanying thrombocytopenia were associated with disease mortality, whereas persistent and gradual increases in lymphocyte responses might be required for effective immunity against MERS-CoV infection. Leukocytosis, primarily due to increased neutrophils and monocytes, was generally observed in more severe and fatal cases. The blood levels of cytokines such as IL-10, IL-15, TGF-β, and EGF were either positively or negatively correlated with disease mortality. Robust induction of various chemokines with differential kinetics was more prominent in patients that recovered from pneumonia than in patients with mild febrile illness or deceased patients. The correlation of the virological and immunological responses with disease severity and mortality, as well as their responses to current antiviral therapy, may have prognostic significance during the early phase of MERS. Supplementary information The online version of this article (doi:10.1038/srep25359) contains supplementary material, which is available to authorized users. INTRODUCTION The Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic pathogen that causes acute and severe respiratory illness with a high mortality rate1. Since 2012, more than 1,600 patients have been reported and the mortality rate approaches 35%2. Primary transmission of MERS-CoV might be mediated by close contact between humans and infected animal reservoirs such as camels3,4. However, in Middle Eastern countries, most MERS cases are associated with human-to-human spread starting in healthcare settings that then spark sporadic outbreaks5. An unexpected large outbreak in South Korea (186 confirmed cases with 38 deaths), initiated by an infected traveler from the Arabian peninsula, was also attributed to nosocomial infections6 and highlights our limited knowledge of this emerging infectious disease7. The major symptoms of MERS cases are acute viral pneumonia often associated with extrapulmonary manifestations such as enteric illness5. Patients infected with MERS-CoV present with a wide range of clinical severity varying from asymptomatic to severe pneumonia with respiratory failure5. Mortality mainly results from acute respiratory distress syndrome (ARDS)4,5,8. Currently, the pathogenesis of the pulmonary and extrapulmonary manifestations of MERS remains poorly defined and knowledge of factors affecting disease severity is limited, although underlying illness, older age, and high viral loads are associated with poorer outcomes5,8,9,10. Since the outbreak of MERS in South Korea was initiated by an infected person, the clinical courses and epidemiological features, including exposure periods, are well documented for most cases6,11. Most patients that developed respiratory illness received a combined antiviral therapy composed of pegylated interferon (IFN)-α, ribavirin, and lopinavir/ritonavir, a treatment with unknown efficacy12,13. We sought to identify the factors dictating disease severity and the outcomes of patients treated with antiviral regimens. Here, we retrospectively analyzed clinical data from fourteen hospitalized MERS patients who collectively represent a wide spectrum of disease severity, ranging from mild febrile illness to fatal pneumonia. In addition, we investigated virological and immunological features of the patients using clinical samples acquired during various stages of MERS progression. Comparative and kinetic analyses may provide valuable insight into the critical factors affecting disease progression and severity as well as the underlying mechanisms contributing to MERS pathogenesis. RESULTS Clinical characteristics of MERS-CoV patientss We reviewed all available clinical and laboratory data of fourteen patients treated in a hospital during the MERS outbreak. The patients were classified into four groups based on the severity and mortality (Table 1, Supplementary Fig. S1, and Supplementary Table S1). Group I patients includes two patients who only developed fever and recovered without developing pneumonia. They recovered without any treatment. Group II includes three patients (P03–P05) who developed mild pneumonia without hypoxemia (Table 1 and Supplementary Table S1). P04 and P05 showed elevated C-reactive protein (CRP, >3 mg/dl) and P05 had elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) (Supplementary Table S1). Four patients (P06–P09) recovered from more prolonged and severe pneumonia, and are classified as group III. Severe pneumonia was defined as pneumonia severity index (PSI) ≥ 60 at initial presentation (Table 1). All patients in this group exhibited elevated liver enzymes and proteinuria during the acute phase. Among them, P09 had pneumonia, rapidly progressing to respiratory failure, and required mechanical ventilation (MV) and extracorporeal membrane oxygenation (ECMO). She also received convalescent plasma therapy twice on days 10 and 16 after symptom onset (Supplementary Fig. 1). Group IV includes five fatal cases (P10–P14). All group IV patients suffered from severe pneumonia and ARDS requiring high flow nasal cannula and/or mechanical ventilation. The deceased patients were older than 60, except for P11, and had underlying illnesses, except for P10. P11 had decompensated liver cirrhosis and poorly controlled blood glucose levels before MERS-CoV infection. P12 was diagnosed with active pulmonary tuberculosis about one week before he encountered a MERS-CoV infected patient. He developed pneumonia two days after the onset of fever and progressed to ARDS within a week. P13 and P14 had comorbidities including chronic pulmonary obstructive disease (COPD) and asthma. They were infected with MERS-CoV while being treated for an acute exacerbation of their pulmonary diseases. They died within 2 weeks after symptom onset despite mechanical ventilation.Table 1Clinical characteristics of MERS patients included in this study.GroupPatient’s ID.AgeSexUnderlying diseases *Incubation period (days)Fever onset to pneumonia (days)Severity of Pneumonia (PSI) **Anti-viral therapy (days) ***Defervescence after the therapy (days) ****O2 therapy (days) *****RecoveredG IP0165F–18–––––P0266F–12–––––G IIP0339F–8329123–P0455F–10445145–P0557F–9447149–G IIIP0660M–54601919–P0763F–65631410NP (1)P0841MFAP427172NP (1)P0961F–146711410MV/ECMO (14/7)DeceasedG IVP1082F–5710211N.D.HFNC (3)P1149MCirrhosis, DM4711910N.D.HFNC (2)P1269MTB3511911N.D.MV (5)P1374MCOPD2214411N.D.MV (7)P1478MCOPD, Asthma, DM23148104MV (4)*FAP: Familial adenomatous polyposis, DM: Diabetes mellitus, COPD: Chronic obstructive pulmonary disease, TB: Tuberculosis.**PSI: Pneumonia severity index at initial presentation.***Anti–viral therapy: combined therapy composed of pegylated interferon (IFN)-alpha 2a, ribavirin, and lopinavir/ritonavir (see details in Supplementary Table S2).****N.D.: No defervescence.*****NP: nasal prong, HFNC: high flow nasal cannula, MV: mechanical ventilation, ECMO: extracorporeal membrane oxygenation. All the patients with pneumonia were treated with anti-viral drugs (Supplementary Table S2) and examined daily by chest X-rays until the resolution of pneumonia. Representative radiologic findings of MERS patents with pneumonia are shown in Fig. 1. Patients with pneumonia almost always showed ground-glass opacity or airspace consolidation involving either or both sides of lower lung fields. Chest computed tomography (CT) was performed on P08 and his chest CT scans revealed lobar consolidation in right lower lobe and segmental infiltration in the left upper lobe. Patients in group II showed more rapid clearing of pneumonic infiltrates compared to patients in group III.Figure 1Representative chest images of the MERS patients.Chest images of the MERS patients suffered from mild (P05) or severe pneumonia (P08 and P13) were presented. P05 and P08 were recovered from the pneumonia whereas P13 died due to ARDS. Images were taken at the indicated days after symptom

Read the complete text